Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 80Leukemia, Myeloid, Acute 74Multiple Myeloma 70Breast Neoplasms 70Lymphoma, Non-Hodgkin 62Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 52Recurrence 51Myelodysplastic Syndromes 50Lymphoma, Follicular 50Lymphoma, B-Cell 47Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Hodgkin Disease 34Melanoma 33Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Neoplasm Metastasis 22Pancreatic Neoplasms 21Leukemia, Biphenotypic, Acute 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

Pancreaticojejunostomy 2obeticholic acid 1fludarabine 1aldesleukin 1X-Rays 1Tissue Adhesives 1Tea 1Stents 1Specimen Handling 1Phantoms, Imaging 1Octreotide 1Iopamidol 1Hydromorphone 1Hydrocortisone 1High-Energy Shock Waves 1Endoscopy, Gastrointestinal 1Endoscopic Mucosal Resection 1Cyclophosphamide 1Bupivacaine 1Biopsy 1Anti-Bacterial Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Duodenal Neoplasms × Cyclophosphamide × 1 year × Clear all
NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡